She Trusted Depo-Provera for Years. Then Came the Diagnosis That Changed Everything.

A Life That Felt Ordinary

She was in her early forties, at the kind of age where life finally feels like it fits. She had a job she was good at — administrative work for a regional healthcare organization, the kind of role that required her to hold a dozen moving pieces together at once, and she was quietly excellent at it. It gave her structure and purpose, and she liked that. She rented a small house in a quiet neighborhood where the neighbors knew each other's names and left packages on porches without worry.

On weekends, she walked her dog along the same trail through the park near her home. The dog was a scruffy mixed-breed named Biscuit — part terrier, part mystery — who had been with her for six years and operated as though the trail were his personal kingdom. She cooked simple dinners. She had a small circle of friends she'd known for more than a decade. She was not someone who sought drama or complication. She was someone who showed up: for work, for the people she loved, for the small rhythms that made a life feel solid.

Depo-Provera had been part of that rhythm for nearly ten years. Her doctor had recommended it when she was in her early thirties, and she'd never had reason to question it. The injection came every three months, like a dentist appointment — practical, unremarkable. She never thought twice about it. It was just a part of life, the way coffee in the morning was a part of life, or the same parking spot at work. It existed in the background, doing its job, asking nothing of her attention.

That ordinariness is worth naming, because it is what made everything that followed so disorienting. She wasn't someone who expected her body to betray her. She exercised, she ate reasonably well, she went to her annual appointments. She was doing everything right. And she was trusting, as most of us do, that the medications prescribed by her doctor were safe — that if there were serious risks, she would have been told about them.

The Appointment That Changed Everything

The headaches had been building for a few months. She noticed them first as a low, persistent pressure behind her eyes — the kind of thing she attributed to screen fatigue, or the stress of a demanding quarter at work. She took ibuprofen. She bought blue-light-blocking glasses. She drank more water. She almost didn't go to the doctor at all. It took a friend who'd been listening to her mention the headaches for the third time in a month to finally say: just go. Make an appointment. It's probably nothing.

It wasn't nothing. The routine appointment turned into imaging. The imaging turned into a referral to a neurologist — a referral she didn't fully understand at the time. The neurologist ordered further scans. And then, in an office that smelled faintly of antiseptic and had fluorescent lights that buzzed just barely audibly, a doctor said the word that changed everything. Meningioma. A tumor on the lining of her brain. He explained it carefully, with charts, with statistics, with measured reassurance about treatment options. She could hear the words but not quite absorb them. The room seemed to shrink around her.

She drove home alone. She hadn't thought to bring anyone — she'd thought it was just a follow-up. She sat in the parking lot of her apartment complex for a long time, engine off, hands in her lap, before she could make herself start the car. She called her closest friend from that parking lot. She didn't know what to say, so she just said: they found something in my brain. The friend said: I'm coming over. And she was there within twenty minutes.

In the days that followed, she tried to research what she'd been told. The medical language was dense and frightening. She learned that meningiomas are the most common type of primary brain tumor. She learned that they grow on the meninges — the membranes that surround the brain and spinal cord. She learned that the word "benign" did not mean harmless. And eventually, she learned something that her doctor had not mentioned at all: that the contraceptive she had been using for nearly a decade may have had something to do with it.

What Is a Meningioma — and What Is the Link to Depo-Provera?

A meningioma is a tumor that arises from the meninges, the three layers of protective tissue surrounding the brain and spinal cord. It is the most common primary brain tumor in adults, accounting for more than one-third of all brain tumor diagnoses. While many meningiomas are classified as benign — meaning they do not spread to other parts of the body — that classification is profoundly misleading as a measure of their impact. Even slow-growing meningiomas exert pressure on the brain, and depending on their location, can cause devastating neurological consequences.

Symptoms of meningioma include persistent or worsening headaches, vision disturbances, hearing loss, cognitive difficulties and memory problems, weakness or numbness in the limbs, speech difficulties, and in some cases, seizures. Many patients report experiencing these symptoms for months or years before receiving a diagnosis, as the gradual onset can mimic stress, aging, or other conditions. Regardless of grade, meningiomas that require surgical intervention carry significant risk — including the risk of permanent neurological damage, lengthy recovery periods, and recurrence.

The connection between Depo-Provera — known generically as medroxyprogesterone acetate, or MPA — and meningioma has been the subject of serious scientific scrutiny. Meningiomas are known to express progesterone receptors, which is why progestogen-based medications have long been investigated as potential risk factors. The most significant research to date appeared in a 2023 study published in the British Medical Journal (BMJ), which analyzed data from more than 18,000 French women and found that those who used injectable medroxyprogesterone acetate for one year or longer had approximately 5.6 times the risk of developing an intracranial meningioma compared to women who had never used the drug. The longer the duration of use, the stronger the association.

Following the publication of this and related research, the U.S. Food and Drug Administration updated its labeling requirements for Depo-Provera, requiring the drug's manufacturer to add warnings about the meningioma risk. Pfizer, which manufactures Depo-Provera, has been named in thousands of lawsuits filed by women across the country who allege that the company had access to data suggesting an elevated meningioma risk — and failed to adequately disclose it to patients and prescribers.

What makes these cases particularly strong from a legal standpoint is the convergence of three critical factors: a well-documented causal link supported by peer-reviewed research, evidence that the manufacturer had or should have had knowledge of the risk, and a large population of women who suffered serious, concrete injuries. Pharmaceutical failure-to-warn cases of this nature have a strong track record in American courts, and the Depo-Provera litigation is being closely watched as one of the most significant pharmaceutical mass torts of the decade.

When Everything Falls Apart

The first thing she had to do was tell her employer she needed time off. She didn't know how much — nobody seemed to be able to give her a clear answer. She tried to keep working through the fear, through the waiting, through the appointments that multiplied. But the headaches got worse, and the concentration she had always relied on began to slip away from her like water through cupped hands. Entire paragraphs of emails would evaporate from her memory within minutes of reading them. She sat in meetings and watched her colleagues talk and could not hold the thread. Eventually she couldn't pretend anymore. She stopped going in.

The financial weight arrived quickly after that. Medical bills came in waves — imaging, specialist consultations, pre-surgical workups — all arriving in envelopes that she started leaving unopened on the counter. Her income had shrunk. Her savings were not nothing, but they were not enough for this. She had a spreadsheet she'd made on a Sunday afternoon in a kind of grim, methodical panic, trying to calculate how long she could sustain the situation. The numbers were not reassuring.

She used to be someone who had a plan. A plan for the week, a plan for the year, a general and comfortable sense of the shape of her future. Those plans dissolved. She stopped making them — not out of despair, exactly, but because the future had become a fog she couldn't see into. She felt unmoored in a way she hadn't experienced since her twenties, when life was supposed to feel uncertain. In your forties, it wasn't supposed to feel like this.

She told a close friend that she felt like she was watching her own life from behind glass. Everything was visible but slightly unreachable, slightly muffled. She was present for it, but not quite in it. The friend listened. Most of them listened, during those months. That was one thing she has said since: the people around her showed up in ways she hadn't known to expect. But none of them could carry the weight that had settled specifically and entirely on her.

The One Who Never Left Her Side

Biscuit seemed to know before she did that something was wrong. In the weeks before the diagnosis — during the headaches, during the increasing fatigue, during the appointments she was still telling herself were routine — he had started following her more closely than usual. He'd always been an independent dog, content to sprawl in a patch of sunlight across the room. But he began staying close, pressing against her leg when she sat on the couch, positioning himself directly beside her when she slept. Dogs don't know what meningiomas are. But they know their person, and Biscuit knew his person was hurting.

During the days she couldn't get out of bed — and there were many of those, especially in the weeks surrounding surgery — he curled up beside her and didn't ask for anything. When she cried, and she cried a great deal during those months, he pressed his head against her leg with a steadiness that she has described as the most uncomplicated kindness she has ever received. He followed her from room to room. He sat with her through every fear, through every appointment-morning dread, through every silent evening when the weight of everything became too much to carry alone.

She has said since, with a specificity that feels earned: "He kept me going when I didn't have anything left." There is a category of love that asks nothing back, that doesn't need you to explain or perform or be okay. Biscuit provided that category, in full, for as long as she needed it. She is not sentimental by nature. But she says it plainly: she does not know if she would have come through those months the same way without him.

Fighting Back: The Road Through Treatment

Her treatment team gave her options, which she appreciated — the sense of having some agency in a situation that had felt entirely beyond her control. After reviewing the imaging, the tumor's location, and its rate of growth, they recommended surgery. The fear of surgery was different from the fear of the diagnosis. The diagnosis had been abstract, a piece of information she had to metabolize. Surgery was concrete and immediate: a date on a calendar, a pre-surgical checklist, a conversation about what to bring to the hospital and what to leave at home. She made lists. Making lists had always been how she dealt with things she couldn't control.

She underwent surgery in the late spring. Recovery was slow and, at times, painful in ways she hadn't fully anticipated. There were complications that required additional monitoring, more imaging, more waiting for results while trying not to let her mind go to the worst of the possibilities. Her closest friend took two weeks off work to be with her. Her mother flew in from out of state. The house was full of people for a while, which was both wonderful and exhausting, because she was someone who had always needed her own quiet.

But piece by piece, she started to come back. It was not dramatic — there was no single morning when she woke up feeling like herself again. It was more incremental than that. The first day she made coffee without thinking about whether she had the energy to do it. The first time she laughed at something on television and then realized, a beat later, that she had laughed — really laughed, unselfconsciously. The first real walk she took with Biscuit when her legs felt strong enough to make it the full length of the trail. She cried after that walk. She couldn't explain exactly why, but she suspects it had something to do with proof: proof that she was still here, still moving, still capable of something as ordinary and irreplaceable as walking her dog.

Follow-up appointments continued for months. She has ongoing monitoring as a precaution against recurrence. That part does not end — not fully, not yet. But she has learned to carry it differently. The surveillance that once felt like a threat has become, over time, something closer to vigilance. She is paying attention to her body now in a way she never had to before. That is not a small thing. It is also not the life she would have chosen. But it is the life she has, and she has found ways to move inside it with something that, on good days, looks very much like grace.

After the Storm: Compensation and a New Beginning

A few months after surgery, a friend who had been following coverage of the Depo-Provera lawsuits sent her a link to an article. She read it slowly, twice. She had known, abstractly, that litigation existed — she'd seen the headlines — but she had never seriously considered that it applied to her. She was not, she had always told herself, someone who sued people. That was for other people, people with different temperaments, people who were more willing to make their private pain into something public and legal and complicated.

But she did some research. What she found changed her thinking. The connection between Depo-Provera and meningioma had been documented in peer-reviewed medical literature. Pfizer, the drug's manufacturer, was already facing thousands of lawsuits from women across the country who had experienced the same diagnosis. Women with her history. Women with her injury. She reached out for a free case review — hesitantly, almost apologetically, because that is the kind of person she is. The process was simpler than she had expected. No one pressured her. An attorney reviewed her medical records, her history of Depo-Provera use, and her diagnosis, and told her she had a strong case. She agreed to move forward.

The months that followed involved paperwork, questions, more documentation than she had anticipated. She gathered records she hadn't thought to keep. Her attorney's office gathered others she couldn't have found on her own. She answered questions about her symptoms, her surgery, her recovery, the financial impact of the past two years. She answered them honestly and completely, because that has always been the only way she knows how to do things.

Eventually, there was a resolution. Compensation. It did not undo what she had been through — nothing could, and she was clear-eyed about that from the beginning. Her brain had been operated on. Her career had been interrupted. Her savings had been depleted. Those things happened and they left marks. But the compensation gave her something she had not had in a very long time: options. Choices. A genuine way forward, rather than the sense that her life had been narrowed to a single terrible corridor with no visible doors. For the first time in two years, she felt like she could plan again.

She Wakes Up Different Now

She lives in a small cabin in the mountains now. She never would have imagined it during her old life — she was a neighborhood person, a coffee-shop person, someone who liked knowing that the grocery store was eight minutes away. But the settlement gave her choices, and one of the choices she made was space. Physical space, quiet space, the kind of mornings where the first thing you see is trees instead of traffic. She moved slowly at first, afraid to trust the quietness, afraid to let herself want the peace she was reaching for. But she reached anyway. And it was there.

She thinks often about the version of herself who sat in that parking lot after the diagnosis, unable to start the car. She wants that woman to know she made it. Not easily, and not without cost, and not without grief — because there is still grief, for the years of ordinary life that were interrupted, for the person she was before the fear settled in. But she made it. The life she is living now — smaller, quieter, more intentional than the life she had before — is a life she chose, rather than one that was handed to her by circumstance. That distinction matters to her enormously.

Hope came back the way spring always does: not all at once, and not with any announcement. One morning she noticed the light through the trees and felt something uncurl in her chest. She started making plans again — small ones first, a trip to a farmer's market, a dinner she wanted to cook. Then larger ones, slower, more careful ones. She still has hard days. She is honest about that. There are still mornings when the memory of that fluorescent-lit office and those carefully delivered words comes back with a sharpness that surprises her. But the hard days no longer feel like the whole story.

Biscuit is still with her, older now, grayer around the muzzle, moving a little more slowly on cold mornings. He still follows her from room to room. He still finds the patch of sunlight nearest to wherever she is sitting. He still presses his head against her leg when the quiet gets too quiet. Some things, she has found, are remarkably consistent. Some forms of loyalty do not change with the weather or the years or whatever else life decides to bring. She considers that one of the things she knows now that she did not know before. She has paid a steep price for it. But she holds it like something true.

Could This Happen to You? Signs You May Have a Claim

Her story is not unique. Thousands of women across the United States have used Depo-Provera for extended periods and subsequently received a meningioma diagnosis — and many of them had no idea the two could be connected. If you have used Depo-Provera and have experienced a brain tumor diagnosis or unexplained neurological symptoms, it is worth understanding whether you may have legal options.

Women who may qualify for a Depo-Provera lawsuit generally share several key characteristics. The litigation is moving quickly, and statutes of limitations vary by state — typically requiring claims to be filed within two to three years of diagnosis or from the date you reasonably discovered the potential connection between Depo-Provera and your condition. This makes the timing of a consultation critically important.

• History of Depo-Provera use: You used Depo-Provera (medroxyprogesterone acetate injectable contraceptive) for any significant period, particularly one year or longer.
• Meningioma diagnosis: You received a diagnosis of meningioma, intracranial meningioma, or another related brain tumor.
• Neurological symptoms: You experienced persistent headaches, vision problems, hearing changes, memory issues, seizures, cognitive difficulties, or other neurological changes during or after your use of Depo-Provera.
• Inadequate warning: You were not clearly and specifically warned about the risk of meningioma before beginning Depo-Provera treatment.
• No prior settlement: You have not previously settled a Depo-Provera claim or signed a release related to this injury.

The legal process begins with a free, no-obligation case review. There is no cost to speak with an attorney, and if you have a viable claim, most attorneys in this area of law work on contingency — meaning you pay nothing unless you recover compensation. Given the time-sensitive nature of filing deadlines, there is meaningful value in seeking a consultation sooner rather than later.

Frequently Asked Questions